Indefinite Delivery Contract SPE2DR25D9628

The federal contract IDV award is a $4,999,999 Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to the woman-owned small business DMS Pharmaceutical Group Inc. The contract has an ultimate completion date of December 31, 2036 and was awarded on August 1, 2025. It is part of the DLA's SPE2DX program and does not utilize any set-asides.

The IDC enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. This includes branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. The contract covers an extensive pharmaceutical portfolio and positions DMS Pharmaceutical Group as a key supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites. This single-award IDC is a crucial component of the DLA's Pharmaceutical Prime Vendor Global Program, which aims to establish multiple regional contracts to increase the DoD's resiliency and access to vital pharmaceuticals during contingencies or natural disasters.